CoChat

High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints

Open access

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

Abstract Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient outcomes. These unsuccessful ICI trials suggest that the tumour infiltrating immunophenotypes, termed here as the immune cell types, states and their spatial location within the tumour microenvironment (TME), were unfavourable for ICI treatment. Defining the tumour infiltrating immune cells may assist with the identification of predictive immunophenotypes within the TME that are favourable for ICI treatment. To define the immunophenotypes within the ccRCC TME, fresh para-tumour (pTME, n = 2), low-grade (LG, n = 4, G1-G2) and high-grade (HG, n = 4, G3-G4) tissue samples from six patients with ccRCC presenting at a tertiary referral hospital underwent spatial transcriptomics sequencing (ST-seq). Within the generated ST-seq datasets, immune cell types and states, termed here as exhausted/pro-tumour state or non-exhausted/anti-tumour state, were identified using multiple publicly available single-cell RNA and T-cell receptor sequencing datasets as references. HG TMEs revealed abundant exhausted/pro-tumour immune cells with no consistent increase in expression of PD-1, PD-L1 and CTLA4 checkpoints and angiogenic genes. Additional HG TME immunophenotype characteristics included: pro-tumour tissue-resident monocytes with consistently increased expression of HAVCR2 and LAG3 checkpoints; an exhausted CD8 + T cells sub-population with stem-like progenitor gene expression; and pro-tumour tumour-associated macrophages and monocytes within the recurrent TME with the expression of TREM2 . Whilst limited by a modest sample size, this study represents the largest ST-seq dataset on human ccRCC. Our study reveals that high-risk ccRCC TMEs are infiltrated by exhausted/pro-tumour immunophenotypes lacking specific checkpoint gene expression confirming that HG ccRCC TME are immunogenic but not ICI favourable.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-023-00441-5

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic of patient characteristics and experiment workflow. The patient characteristics (a) of the six ccRCC patients (n = 3 LG and n = 3 HG) include: patient LG_2 with a vena cava thrombus (VCT) for which we collected primary tumour microenvironment (TME) and thrombi separately but processed in the one capture array for ST-seq; patient HG_1 that we collected and processed tissues from para-TME (pTME) and TME; and patient HG_3 that we collected tissues from pTME and TME. For this experimental workflow (b), ten tissue regions were sampled from pTME, TME and VCT that excluded fibrotic and necrotic regions. ST-seq was completed using 10x Genomics Visium Gene Expression microarrayed glass slides with unique spatially barcoded ST-spots that captured the mRNA released from the overlaying thin ccRCC tissue sections. Annotation of immune ST-spots was completed with data integration of six published single-cell RNA-sequencing (scRNA-seq) datasets. Further immune cell sub-typing was completed with a scRNA and T-cell receptor (TCR) sequencing dataset. Integrated analysis was completed on CD8+ T cells, TAM and monocytes.
Fig. 1 Schematic of patient characteristics and experiment workflow. The patient characteristics (a) of the six ccRCC patients (n = 3 LG and n = 3 HG) include: patient LG_2 with a vena cava thrombus (VCT) for which we collected primary tumour microenvironment (TME) and thrombi separately but processed in the one capture array for ST-seq; patient HG_1 that we collected and processed tissues from para-TME (pTME) and TME; and patient HG_3 that we collected tissues from pTME and TME. For this experimental workflow (b), ten tissue regions were sampled from pTME, TME and VCT that excluded fibrotic and necrotic regions. ST-seq was completed using 10x Genomics Visium Gene Expression microarrayed glass slides with unique spatially barcoded ST-spots that captured the mRNA released from the overlaying thin ccRCC tissue sections. Annotation of immune ST-spots was completed with data integration of six published single-cell RNA-sequencing (scRNA-seq) datasets. Further immune cell sub-typing was completed with a scRNA and T-cell receptor (TCR) sequencing dataset. Integrated analysis was completed on CD8+ T cells, TAM and monocytes.CC BY · PubMed Central
Fig. 2 Proportions of CD8+ T cell, TAM and monocyte sub-types within the ccRCC TME. The proportion of immune ST-spots (a) increased with ccRCC grade. Further immune cell typing of the immune ST-spots revealed higher proportions of T cells (CD8+ and CD4+ T cells) in pTME and HG TME and macrophages in LG TME (b). Within the identified proportion of CD8+ T cellS, finer sub-typing (c) identified abundant non-exhausted CD8+ NK-like and tissue-resident cells in the pTME, LG TMEs and HG_2 TME. In contrast, exhausted CD8+ T cells were identified in HG_1 and HG_3 TMEs. TAM and monocyte sub-typing (d) identified non-exhausted TAM ISGint cells within all LG and HG_2 TMEs. Abundant exhausted tissue-resident monocytes were identified in HG_1 and HG_3 TMEs. Similarly, exhausted TAM HLAint and TAM ISGhi were identified in pHG_1.1 and pHG_3.1. The proportion of CD8+ T cell (c), TAM and monocyte (d) sub-types are based on the immune cell types (b) and immune ST-spots (a) proportions. Within the HG TMEs, we further investigated heterogeneity within CD8+ T cells (e). For the HG TMEs, we found sub-populations within the exhausted CD8+ T cells expressing progenitor (TCF7) or immunomodulatory (ENTPD1) genes. Spatial mapping of the variable proportions of CD8+ T cells, TAM and monocytes (f) within HG ccRCC TMEs demonstrated abundant pro-tumour tissue-resident monocytes surrounding the exhausted CD8+ T-cell sub-types within defined tumour/immune admixed regions, as presented within the representative HG_1.2 TME.
Fig. 2 Proportions of CD8+ T cell, TAM and monocyte sub-types within the ccRCC TME. The proportion of immune ST-spots (a) increased with ccRCC grade. Further immune cell typing of the immune ST-spots revealed higher proportions of T cells (CD8+ and CD4+ T cells) in pTME and HG TME and macrophages in LG TME (b). Within the identified proportion of CD8+ T cellS, finer sub-typing (c) identified abundant non-exhausted CD8+ NK-like and tissue-resident cells in the pTME, LG TMEs and HG_2 TME. In contrast, exhausted CD8+ T cells were identified in HG_1 and HG_3 TMEs. TAM and monocyte sub-typing (d) identified non-exhausted TAM ISGint cells within all LG and HG_2 TMEs. Abundant exhausted tissue-resident monocytes were identified in HG_1 and HG_3 TMEs. Similarly, exhausted TAM HLAint and TAM ISGhi were identified in pHG_1.1 and pHG_3.1. The proportion of CD8+ T cell (c), TAM and monocyte (d) sub-types are based on the immune cell types (b) and immune ST-spots (a) proportions. Within the HG TMEs, we further investigated heterogeneity within CD8+ T cells (e). For the HG TMEs, we found sub-populations within the exhausted CD8+ T cells expressing progenitor (TCF7) or immunomodulatory (ENTPD1) genes. Spatial mapping of the variable proportions of CD8+ T cells, TAM and monocytes (f) within HG ccRCC TMEs demonstrated abundant pro-tumour tissue-resident monocytes surrounding the exhausted CD8+ T-cell sub-types within defined tumour/immune admixed regions, as presented within the representative HG_1.2 TME.CC BY · PubMed Central
Fig. 3 Targetable and novel IC and angiogenic gene expression within CD8+ T cells, TAM and monocytes. Targetable and novel ICs (a, c) demonstrated subtle relative increased expression within CD8+ proliferative cells for HG_1.2, HG_1.3 and HG_3.2 TMEs. Novel IC HAVCR2 demonstrated a consistent increased expression within the exhausted tissue-resident monocytes across all TMEs. Novel IC LAG3 demonstrated increased expression within exhausted TAM ISGhi and tissue-resident monocytes in HG_1 and HG_3 TMEs. Targetable and novel angiogenic genes (b, d) demonstrated no consistent increased expression within CD8+ T cells, TAM and monocytes.
Fig. 3 Targetable and novel IC and angiogenic gene expression within CD8+ T cells, TAM and monocytes. Targetable and novel ICs (a, c) demonstrated subtle relative increased expression within CD8+ proliferative cells for HG_1.2, HG_1.3 and HG_3.2 TMEs. Novel IC HAVCR2 demonstrated a consistent increased expression within the exhausted tissue-resident monocytes across all TMEs. Novel IC LAG3 demonstrated increased expression within exhausted TAM ISGhi and tissue-resident monocytes in HG_1 and HG_3 TMEs. Targetable and novel angiogenic genes (b, d) demonstrated no consistent increased expression within CD8+ T cells, TAM and monocytes.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 26

Metadata

Authors
Raghubar, A. M., Matigian, N. A., Crawford, J., Francis, L., Ellis, R., Healy, H. G., Kassianos, A. J., Ng, M. S. Y., Roberts, M. J., Wood, S., & Mallett, A. J.
Affiliations
  • Queensland Health (AU)
  • The University of Queensland (AU)
Corresponding author
Mallett, Andrew J.
Venue
npj Precision Oncology
Published
2023-09-11
Volume
7
Issue
1
Pages
88-88
ISSN
2397-768X (ISSN-L)
OpenAlex
W4386603347
Cited by
26
References
61
Citations by year
2026: 12 · 2025: 7 · 2024: 6 · 2023: 1
FWCI
3.17
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ResearchOnline - JCU (James Cook University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Queensland Health Advancing Clinical Research Fellowship
  • Australian Government Research Training Program Scholarship
  • Royal Brisbane and Women’s Hospital Foundation 2020 Robert and Janelle Bird Postdoctoral Research Fellowship
  • Metro North Hospital and Health Service Clinical Research Fellowship
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
clear cell renal cell carcinoma, tumor microenvironment, immune checkpoint inhibitors, immune exhaustion, spatial transcriptomics, tumour-associated macrophages, CD8+ T cells, PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, TREM2, tumor grade, immunogenicity, predictive biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints. https://app.cochat.ai/papers/10.1038/s41698-023-00441-5
The paper
Raghubar, A. M., Matigian, N. A., Crawford, J., Francis, L., Ellis, R., Healy, H. G., Kassianos, A. J., Ng, M. S. Y., Roberts, M. J., Wood, S., & Mallett, A. J. (2023). High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints. npj Precision Oncology. https://doi.org/10.1038/s41698-023-00441-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.